From One Month To One Year Post-launch, The User-base Of Roche/Genentech/Chugai's Perjeta Has More Than Doubled Moreover, the Majority of Oncologists Who Have Not Yet Prescribed Perjeta Intend to Do So in the Next Three Months, According to a New Report from BioTrends Research Group PR Newswire EXTON, Pa., Aug. 13, 2013 EXTON, Pa., Aug. 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one year post-launch, the user-base of Roche/Genentech/Chugai's Perjeta has more than doubled since BioTrends first assessed physician uptake one month post-launch. According to LaunchTrends®: Perjeta and Kadcyla (US), after approximately one year on the market, 77 percent of surveyed U.S. oncologists have prescribed Perjeta (pertuzumab) in an average of six of their HER2-overexpressing (HER2+) breast cancer patients. However, of those physicians who have not already prescribed Perjeta, 76 percent intend to do so in the next three months. Approximately five percent of surveyed oncologists do not plan on prescribing Perjeta in the future. The report also focuses on uptake of Roche/Genentech/Chugai's Kadcyla (ado-trastuzumab emtansine); approximately four months after launch, almost two-thirds of surveyed oncologists have now prescribed Kadcyla in an average of seven of their HER2+ patients. Of non-prescribers, 97 percent plan on prescribing Kadcyla in the next year. "Based on the study data, Perjeta and Kadcyla treatment rates are anticipated to increase considerably in the next year," said Decision Resources Group Principal Analyst Amy Duval, M.Res. "This will likely translate into a substantial increase in both the user- and patient-base for both treatment options." The recently published report also finds that more than 90 percent of current Perjeta and Kadcyla users are moderately-to-highly satisfied with the products, typically citing that their high satisfaction is attributed to patients having an initial positive response to treatment, in addition to good tolerability profiles of the drugs. LaunchTrends: Perjeta and Kadcyla (US) is a four-wave syndicated report series designed to track the uptake of Perjeta at one month, three months, six months, one year and one year and nine months after the launch of Perjeta, and four months and one year following Kadcyla's commercial availability based upon primary research with U.S. oncologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. In the current wave of research, BioTrends surveyed 74 U.S. oncologists in June 2013 and conducted qualitative interviews with a subset of 15 of the respondents in June 2013. About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group atwww.DecisionResourcesGroup.com. All company, brand, or product names contained in this document may be trademarks of their respective holders. For more information, contact: Decision Resources Group Christopher Comfort 781-993-2597 firstname.lastname@example.org SOURCE BioTrends Research Group Website: http://www.bio-trends.com
From One Month To One Year Post-launch, The User-base Of Roche/Genentech/Chugai's Perjeta Has More Than Doubled
Press spacebar to pause and continue. Press esc to stop.